Biodesix Inc investor relations material

Biodesix, Inc. acquires and operates diagnostic companies, as well as develops and commercializes diagnostic tests in the areas of lung cancer, malignancies, and other diseases. The company provides a multi-protein blood test, which includes Nodality gene mutational panel for use in non-small-cell lung cancer (NSCLC) patients; and Biodesix Lung Reflex testing platform that analyzes circulating tumor DNA in advanced stage NSCLC patients. Biodesix, Inc. was founded in 2002 and is based in Boulder, Colorado with additional offices in California and Germany.